Purple Biotech Ltd (PPBT) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, lacks significant positive catalysts, and has poor financial performance. While the options data indicates minimal trading sentiment, there are no compelling signals or trends to suggest immediate upside potential. Given the investor's profile and the current data, holding off on investment is recommended.

Technical Analysis

The stock exhibits bearish technical indicators. The MACD histogram is negative and expanding downward, RSI is neutral at 31.366, and moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support is at 0.48, and resistance is at 0.534. Pre-market price is down 1.12%, indicating continued weakness.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows minimal activity with a put-call ratio of 0.01, indicating negligible bearish sentiment. Implied volatility is high at 588.02, suggesting elevated risk.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No significant hedge fund or insider trading trends. No recent congress trading data. No AI Stock Picker or SwingMax signals.

Neutral/Negative Catalysts

is also down 0.41%.

Financial Performance

In 2025/Q3, the company reported no revenue growth (0.00% YoY) and a net loss of -$1,303,000, despite a 96.53% YoY improvement. EPS and gross margin remain at 0, indicating poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast PPBT stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.450

Low

Averages

High